Diamorphine
- Generic Name
- Diamorphine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23NO5
- CAS Number
- 561-27-3
- Unique Ingredient Identifier
- 70D95007SX
- Background
Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs. As heroin, it is illegal to manufacture, possess, or sell in the United States and the UK. However, under the name diamorphine, heroin is a legal prescription drug in the United Kingdom.
- Indication
Diamorphine, as a prescription medication in the United Kingdom, is indicated for use in the treatment of severe pain associated with surgical procedures, myocardial infarction or pain in the terminally ill and for the relief of dyspnoea in acute pulmonary edema .
- Associated Conditions
- -
- Associated Therapies
- -
Jackson County's deflection program to prioritize Greenway | Crime & Justice
Jackson County's new deflection program, launching Oct. 7, offers resources and incentives for those caught with small amounts of drugs to seek treatment, dropping criminal charges if they comply with treatment requirements, including 10 meaningful engagements with counselors.
Lincoln County hopes to have new state-funded drug "deflection" programs running by ...
Oregon's drug decriminalization law changes lead to better arrest options for low-level offenders, offering treatment or jail. Lincoln County's program, funded by $341,256, faces delays and internal debate over the deflection coordinator's placement, currently unresolved.
Recreational drug use tied to repeat cardiovascular events
Recreational drug use triples risk for repeat serious cardiovascular events within one year of hospitalization, according to a study presented at the European Society of Cardiology Congress 2024. The study, involving 1,392 patients, found that 11% tested positive for recreational drugs, with 7% experiencing major adverse cardiovascular and cerebrovascular events (MACCE) at one year, significantly higher among drug users (13% vs. 6%).
UK bans xylazine and 21 other substances to fight drug abuse
UK introduces legislation to ban xylazine, known as the 'zombie drug', and 21 other substances to combat drug-related deaths and disrupt drug gangs. Xylazine, a powerful sedative, is increasingly mixed with opioids and detected in cannabis vapes, causing severe health issues. The UK's move to classify xylazine as a Class C drug follows ACMD recommendations, placing the UK ahead of other nations in xylazine control. The legislation targets 22 substances, with six earmarked for Class A control, potentially resulting in life imprisonment for production or distribution.
Recreational Drug Use Triples Odds for Repeat Heart Crises
Recreational drug use triples the risk of repeat heart crises within a year, with MDMA users four times more likely, according to a study by Dr. Raphael Mirailles.
Scotland’s drug deaths remain worst in Europe amid ‘concerning’ 12% increase
Scotland's drug deaths rose by 12% in 2023, with 1,172 fatalities, the highest in Europe. Opioids were involved in 80% of deaths, with a notable increase in synthetic opioids like nitazenes. Efforts to improve treatment and reduce harm continue, but targets for increasing treatment access remain unmet.
FDA rejects psychedelic MDMA as treatment for PTSD, calling for additional study
FDA declined approval for MDMA as PTSD therapy, citing insufficient data and safety concerns, despite advocacy from veterans and mental health groups. Lykos Therapeutics plans to request reconsideration. This decision impacts the broader push for psychedelic treatments, with ongoing research into substances like psilocybin for mental health conditions.
The Drug That Could Help End the Opioid Epidemic
Buprenorphine, a proven effective medication for opioid addiction, sees low uptake in the U.S. despite federal efforts to increase access. Cultural and personal beliefs about addiction and recovery, alongside policy and cost barriers, hinder its adoption. Stories of individuals like Mallory and Quincie highlight the drug's life-saving potential and the complex challenges of opioid addiction treatment.
Key FDA researcher who evaluated OxyContin for agency now lives in northern New Hampshire town
Littleton, NH, a picturesque mountain town, faces a severe opioid crisis, with 10 overdose deaths in 2017. Dr. Curtis Wright, a former FDA researcher who approved OxyContin and later worked for Purdue Pharma, resides there. The community, led by Police Chief Paul Smith, focuses on engagement over enforcement, with seven sober living homes now aiding recovery.
5 Things podcast: amid opioid crisis, SCOTUS to hear Sackler case
The opioid crisis, linked to over 600,000 deaths, implicates the Sackler family and Purdue Pharma. The Supreme Court is reviewing a $6 billion settlement that would shield the Sacklers from future lawsuits, with arguments set for December. The case examines the balance between compensating victims and holding the Sacklers accountable, amidst debates on the ethical implications of their wealth and philanthropy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath